Drug-labels.com

Vinorelbine Injection, USP (Generic Medical Partners): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
10 mg
Active ingredient:
ATC code:
Similar drugs:

Source: Health Canada – Drug Product Database (DPD) and product monographs · About this document

Patient Medication Information: uses, side effects, how to take - Vinorelbine Injection, USP (Generic Medical Partners)

ABOUT THIS MEDICATION

What the medication is used for:

VINORELBINE INJECTION, USP has been prescribed to you for the treatment of lung and/or breast cancer.

What it does:

Vinorelbine interferes with the growth of rapidly dividing cells, like cancer cells, and eventually causes cell death.

When it should not be used:

VINORELBINE INJECTION, USP should not be used if you:

  • are allergic to vinorelbine tartrate or

  • have severe granulocytopenia (reduced number of white

    blood cells) or severe thrombocytopenia (reduced number of platelets. Platelets help to form blood clots).

What the medicinal ingredient is:

Vinorelbine Tartrate

What the nonmedicinal ingredients are:

Water for Injection

What dosage forms it comes in:

Injection 10 mg/mL

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

  • The preparation and administration of VINORELBINE INJECTION, USP (vinorelbine tartrate) is only carried out by trained healthcare professionals
  • Before each administration of VINORELBINE INJECTION, USP, a blood sample will be taken for analysis of its components
  • If the results of this analysis are not satisfactory, your treatment may be delayed or the dose reduced and further checks may be made

BEFORE you use VINORELBINE INJECTION, USP talk to your doctor or pharmacist if:

  • you have any other medical problems, especially any infections such as chickenpox (including recent exposure) or Herpes zoster (shingles)
  • you are taking any medications, prescription and non- prescription medicines
  • you have had any other therapy for cancer including other drugs or radiation therapy.

  • you are pregnant or if you intend to have children. Vinorelbine may cause birth defects if either the male or female is receiving it at the time of conception or if it is taken during pregnancy

  • you intend to breast-feed during treatment with vinorelbine. Vinorelbine may cause serious side effects in nursing babies.
  • you have ever had any unusual or allergic reaction to vinorelbine

INTERACTIONS WITH THIS MEDICATION

Tell your doctor about all medications that you are taking. It is especially important that your doctor knows if you are taking mitomycin, cisplatin or paclitaxel.

You may experience radiosensitivity effects if you take vinorelbine tartrate injection prior or along with radiation therapy.

PROPER USE OF THIS MEDICATION

VINORELBINE INJECTION, USP is for intravenous administration only. It should be administered by individuals experienced in the administration of cancer chemotherapeutic drugs.

Usual dose:

The dose of vinorelbine will be different for different patients. The dose that is used may depend on a number of things, including what the medicine is being used for, your body size, and whether or not other medicines are also being taken.

Overdose:

If you think you have taken too much VINORELBINE INJECTION, USP, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

In the case of an overdose your doctor will stop the therapy and treat the symptoms. You may have to have additional medical treatment.

Missed Dose:

Your doctor will set the times at which you are to receive this medicine. It is important not to miss a dose. Let your prescriber or health care professional know if you are unable to keep an appointment. Contact your doctor as soon as possible.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Any medicine may have unwanted effects. Tell your doctor about any unusual sign or symptom whether listed or not.

Some side-effects that have been reported following treatment with vinorelbine tartrate are listed below.

  • Constipation, rarely becoming intestinal obstruction
  • Diarrhea
  • Nausea and occasionally vomiting.
  • Breathing difficulties or skin reaction as a result of an allergic reaction.
  • Alopecia (hair loss).
  • Jaw pain.
  • A burning feeling and inflammation at the site of injection may occur. VINORELBINE INJECTION, USP is a vesicant (can cause skin blistering) and can produce phlebitis (inflammation of a vein) or extravasation (escape of drug and or blood, from a vessel into the surrounding tissue) injury.

If you notice pain, swelling, burning or any unusual feeling around the site of your injection, tell your health

care professional immediately.

  • Decrease in white blood cells, red blood cells and platelets. The major toxicities of vinorelbine tartrate are related to bone marrow toxicity, specifically granulocytopenia (decrease in white blood cells) with increased susceptibility to infection. Contact your doctor immediately if you experience fever or chills.
  • Neuropathy (suppression of some reflex reactions or altered touch awareness).
  • Asthenia (The lack or loss of strength and energy, weakness)
SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom / effectTalk with your doctor or pharmacistStop taking drug and call your doctor or pharmacist
Only if severeIn all cases
Common

Fever, chills

Diarrhea and

Constipation

Numbness of finger tips and toes

At injection site

Pain

Swelling

Burning

✓

✓

✓

✓

✓

✓

This is not a complete list of side effects. For any unexpected effects while taking VINORELBINE INJECTION, USP, contact your doctor or pharmacist.

HOW TO STORE IT

Store VINORELBINE INJECTION, USP vials in refrigerator (2°C to 8°C) in the original package protected from light. Do not freeze.

Keep out of the sight and reach of children.

Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

  • Online at MedEffect (http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php);
  • By calling 1-866-234-2345 (toll-free);

  • By completing a Consumer Side Effect Reporting Form and sending it by:

    • Fax to 1-866-678-6789 (toll-free), or

    • Mail to: Canada Vigilance Program

      Health Canada, Postal Locator 0701E Ottawa, ON

      K1A 0K9

      Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect (http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php).

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found by contacting the sponsor, Generic Medical Partners Inc. at:

1.416.444.4GMP (1.416.444.4467)

Generic Medical Partners Inc.,

251 Consumers Road, Suite 1200

Toronto, Ontario,

M2J 4R3

Last revised: September 03, 2014

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02431130

Revision date stated in the text: September 3, 2014

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Vinorelbine Injection, USP (Generic Medical Partners)

Rx or OTC
Prescription (Rx)?
DIN 02431130
Schedule(s) PRESCRIPTION
Active ingredient(s) Vinorelbine (vinorelbine tartrate) 10 MG
Dosage form(s) Solution
Route(s) of administration Intravenous
Drug class (WHO ATC)
  1. L Antineoplastic and immunomodulating agents
    1. L01 Antineoplastic agents
      1. L01C Plant alkaloids and other natural products, antineoplastic drugs
        1. L01CA Vinca alkaloids and analogues, antineoplastic
          1. L01CA04 Vinorelbine
Company GENERIC MEDICAL PARTNERS INC
Current status Marketed
Current status date August 1, 2017

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.